Literature DB >> 22386633

Satisfaction with antiepileptic drugs in children and adolescents with newly diagnosed and chronic epilepsy.

Ettore Beghi1, Paolo Messina, Elisabetta Pupillo, Giovanni Crichiutti, Maria Giuseppina Baglietto, Pierangelo Veggiotti, Nelia Zamponi, Susanna Casellato, Lucia Margari, Carlo Cianchetti.   

Abstract

PURPOSE: To assess incidence, indicators and outcome of satisfaction with antiepileptic drugs in children.
METHODS: Multicenter, observational, open, prospective survey of children and adolescents with epilepsy with three-month follow-up. Included were patients aged 3-17 years with newly diagnosed ("new diagnosis") or chronic epilepsy ("old diagnosis") requiring treatment start or change. Satisfaction was assessed with the Hedonic Visual Scale or direct questions, depending on patient's age. Quality of life of adolescents (QOLIE-48) and of caregivers (SF-36) and predictors of (dis)satisfaction were also assessed.
RESULTS: 293 patients completed the study. Most had generalized idiopathic epilepsy, and a disease lasting <12 months. Newly diagnosed patients were 60.8%. Patients declaring satisfaction were 70.6% at one month and 75.8% at three months. Compared to old diagnosis, new diagnosis carried a higher satisfaction rate and improved satisfaction at end of follow-up. Independent predictors of dissatisfaction were an old diagnosis, adverse events and SF-36 score. The latter remained the only independent predictor of persisting dissatisfaction when adjusting for the presence of and the interaction with adverse events.
CONCLUSIONS: About one-fourth of children and adolescents with epilepsy are dissatisfied with treatment. Chronic epilepsy, adverse events, and parents/caregivers with poor quality of life predict dissatisfaction.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386633     DOI: 10.1016/j.eplepsyres.2012.02.005

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  3 in total

Review 1.  A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.

Authors:  Rodrigo Rocamora
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

Review 2.  Clinical utility of eslicarbazepine: current evidence.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Massimo Cincotta; Alessia Carelli; Alberto Verrotti
Journal:  Drug Des Devel Ther       Date:  2015-02-10       Impact factor: 4.162

Review 3.  Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy.

Authors:  Renato Tambucci; Claudia Basti; Maria Maresca; Giangennaro Coppola; Alberto Verrotti
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-23       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.